* Takeda receives European Commission approval of adcetris
(brentuximab vedotin) for consolidation treatment in
post-transplant hodgkin lymphoma
Source text for Eikon:
Further company coverage:
…
The post BRIEF-Takeda receives EC approval of adcetris for post-transplant hodgkin lymphoma appeared first on NASDAQ.